Tag: Full

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

by  on  in Business Financial News

  • The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation.

  • The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded.

VICTORIA, British Columbia, July 07, 2023–(BUSINESS WIRE)–IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023.

“As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive strides we made in the previous year. In the fiscal year ended April 30, 2023, we achieved a revenue of $20.7 million, marking a notable 6.7% (or 9% when adjusting for the effects of currency translation) increase compared to the year ended April 30, 2022. We also recorded our highest quarterly revenue total of $5.6 million in the last quarter ending April 30, 2023. These milestones serve as a testament to the soundness of our strategies and the dedication of our team.

As we look ahead to Fiscal Year 2024, we see immense potential for our in silico suite of services and data management capabilities to further bolster our growth. We expect these innovative offerings to significantly contribute to our financial performance this year and set the stage for long-term success.

Our unwavering commitment to excellence, coupled with our robust pipeline and agile execution, position us to deliver continued strong performance this year and beyond. This is a thrilling period for our company, and we are eager to embark on the new fiscal year, further driving innovation and growth.” Stated Dr.

… Read More ...

Exscientia Business and Financial Update for the Full Year 2022

by  on  in Business Financial News

OXFORD, U.K., March 23, 2023–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI)

Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT.

“2022 was marked by significant milestones for Exscientia, including signing a groundbreaking strategic collaboration with Sanofi, as we continue to validate our end-to-end platform of AI-driven tools and distinguish ourselves as leaders in AI-based drug design, discovery and development,” said Professor Andrew Hopkins, D.Phil., founder and Chief Executive Officer of Exscientia. “We also initiated IGNITE, a Phase 1/2 study of our A2A receptor antagonist EXS21546 (‘546), and are using the clinical data to further confirm biomarker accuracy in selecting patients likely to respond best to treatment. More recently, last month, Bristol Myers Squibb initiated a first-in-human study of EXS4318 (‘4318), our fourth AI-designed molecule to enter the clinic and the first in inflammatory disease. Looking at progress to date, we remain very confident in our differentiated approach and our company’s ability to bring innovative, high-quality treatments to patients faster and more efficiently than today’s industry standard.”

Recent Highlights

Internal pipeline

  • In March 2023, Exscientia highlighted two new differentiated precision oncology programmes in IND-enabling studies; EXS74539 (‘539), a reversible and brain penetrant LSD1 inhibitor and EXS73565 (‘565), an allosteric MALT1 protease inhibitor

  • In November 2022, Exscientia initiated IGNITE, a Phase 1/2 study of its A2A product candidate, ‘546, with the first patient expected to be enrolled in the first half of 2023

    • The trial is examining the safety, efficacy, pharmacokinetics and pharmacodynamics of ‘546 when used in combination with anti-PD-1 therapy in renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC), and will enrol

… Read More ...

Dell Technologies Delivers Fourth Quarter and Full Year Fiscal 2023 Financial Results

by  on  in Business Financial News

News summary

  • Record full-year revenue of $102.3 billion, up 1%, and fourth quarter revenue of $25 billion, down 11%
  • Record full-year operating income of $5.8 billion, up 24%, and record non-GAAP operating income of $8.6 billion, up 11%
  • Full-year diluted earnings per share at $3.24, and non-GAAP diluted earnings per share at $7.61
  • Announcing a 12% increase in annual cash dividend to $1.48 per common share

ROUND ROCK, Texas, March 2, 2023 /PRNewswire/ — 

Full story
Dell Technologies (NYSE: DELL) announces financial results for its fiscal 2023 fourth quarter and full year. Revenue for the year was a record $102.3 billion, up 1% over fiscal year 2022. The company generated record operating income of $5.8 billion, up 24% over the prior year, and record non-GAAP operating income of $8.6 billion, up 11%. For the full year, net income from continuing operations was $2.4 billion and non-GAAP net income was $5.7 billion. Cash flow from operations was $3.6 billion. Full-year diluted earnings per share from continuing operations was $3.24, and non-GAAP diluted earnings per share was $7.61.

Fourth quarter revenue was $25 billion, down 11%. Operating income was $1.2 billion, representing 4.7% of revenue, and non-GAAP operating income was $2.2 billion, representing 8.7% of revenue. Net income from continuing operations for the quarter was $606 million, and non-GAAP net income was $1.3 billion. Cash flow from operations for the quarter was $2.7 billion. Diluted earnings per share from continuing operations was $0.84, and non-GAAP diluted earnings per share was $1.80.

Dell ended the quarter with remaining performance obligations of $40 billion, deferred revenue of $30.3 billion and recurring revenue of approximately $5.6 billion, up 12% year-over-year. Cash

… Read More ...

TTEC Announces Fourth Quarter and Full Year 2022 Financial Results

by  on  in Business Financial News

Full Year 2022
Revenue was $2.444 Billion, up 7.5 Percent and 9.4 Percent on a Constant Currency Basis
Operating Income was $168.5 Million or 6.9 Percent of Revenue
($248.5 Million or 10.2 Percent of Revenue Non-GAAP)
Net Income was $117.3 Million or 4.8 Percent of Revenue
($174.4 Million or 7.1 Percent of Revenue Non-GAAP)
Adjusted EBITDA was $326.6 Million or 13.4 Percent of Revenue
Fully Diluted EPS was $2.48 ($3.68 Non-GAAP)

Full Year Bookings of $762 Million

Fourth Quarter 2022
Revenue was $658.3 Million, up 7.5 Percent and 9.6 Percent on a Constant Currency Basis
Operating Income was $48.7 Million or 7.4 Percent of Revenue
($69.9 Million or 10.6 Percent of Revenue Non-GAAP)
Net Income was $25.6 Million or 3.9 Percent of Revenue
($42.0 Million or 6.4 Percent of Revenue Non-GAAP)
Adjusted EBITDA was $84.8 Million or 12.9 Percent of Revenue
Fully Diluted EPS was $0.54 ($0.89 Non-GAAP)

Fourth Quarter Bookings of $197 Million

Provides Outlook for Full Year 2023

DENVER, Feb. 27, 2023 /PRNewswire/ — TTEC Holdings, Inc. (NASDAQ: TTEC), one of the largest, global CX (customer experience) technology and services innovators for end-to-end digital CX solutions, announced today financial results for the fourth quarter and full year ended December 31, 2022.

“We ended 2022 with solid execution and financial results despite the increased uncertainties surrounding the macroeconomic environment. Our performance reflects our broad and diverse base of global clients, our expertise across key strategic verticals, and our full range of CX technology, AI, and service capabilities,” commented Ken Tuchman, chairman and chief executive officer of TTEC. “In this dynamic environment, we will continue to execute on our strategy to accelerate the diversification of our geographic and language footprint, and capitalize on the growing adoption of the

… Read More ...